

# Nasheed M Hossain

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3965443/publications.pdf>

Version: 2024-02-01

21  
papers

592  
citations

1040018

9  
h-index

888047

17  
g-index

22  
all docs

22  
docs citations

22  
times ranked

815  
citing authors

#	ARTICLE	IF	CITATIONS
1	Maintenance therapy after second autologous hematopoietic cell transplantation for multiple myeloma. A CIBMTR analysis. <i>Bone Marrow Transplantation</i> , 2022, 57, 31-37.	2.4	4
2	Genetic Modification of T Cells for the Immunotherapy of Cancer. <i>Vaccines</i> , 2022, 10, 457.	4.4	2
3	<sc>COVID</sc>â€19 thromboembolism incidence, risk factors, and anticoagulation practices from a Chicago metropolitan <sc>US</sc> population. <i>American Journal of Hematology</i> , 2022, 97, .	4.1	0
4	Association of Chronic Graft-versus-Host Disease with Late Effects following Allogeneic Hematopoietic Cell Transplantation for Children with Hematologic Malignancy. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 712.e1-712.e8.	1.2	3
5	Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 2108-2117.	2.4	6
6	Expanding the Toolbox of Adoptive Cell Immunotherapy. <i>Journal of Clinical Oncology</i> , 2021, 39, 1479-1482.	1.6	0
7	CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. <i>Nature Medicine</i> , 2021, 27, 1419-1431.	30.7	273
8	Monitoring of Circulating Tumor DNA Improves Early Relapse Detection After Axicabtagene Ciloleucl Infusion in Large B-Cell Lymphoma: Results of a Prospective Multi-Institutional Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 3034-3043.	1.6	76
9	Late Events After CD-19 CAR-T Treatment. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e1-e2.	2.0	2
10	Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 472-479.	2.0	21
11	Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients. <i>Leukemia and Lymphoma</i> , 2020, 61, 2811-2820.	1.3	7
12	Real World Outcomes of Sars-Cov-2 Thrombosis Rates across Three University Health Systems in the Chicago Metropolitan Area. <i>Blood</i> , 2020, 136, 58-59.	1.4	1
13	Impact of immunoparesis on clinical outcomes following bone marrow transplantation.. <i>Journal of Clinical Oncology</i> , 2020, 38, e20505-e20505.	1.6	0
14	Circulating tumor DNA assessment in patients with diffuse large B-cell lymphoma following CAR T-cell therapy. <i>Leukemia and Lymphoma</i> , 2019, 60, 503-506.	1.3	26
15	Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamideâ€Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1859-1868.	2.0	58
16	Phase I Trial Using CD19/CD22 Bispecific CAR T Cells in Pediatric and Adult Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2019, 134, 744-744.	1.4	42
17	Detectable Circulating Tumor DNA 28 Days after the CD19 CAR T-Cell Therapy, Axicabtagene Ciloleucl, Is Associated with Poor Outcomes in Patients with Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2019, 134, 884-884.	1.4	13
18	Liposomal Daunorubicin/Cytarabine As a Bridge to Donor Lymphocyte Infusion or Allogeneic Stem Cell Transplantation for High-Risk Acute Myelogenous Leukemia. <i>Blood</i> , 2019, 134, 5726-5726.	1.4	0

#	ARTICLE	IF	CITATIONS
19	Phase I Experience with a Bi-Specific CAR Targeting CD19 and CD22 in Adults with B-Cell Malignancies. Blood, 2018, 132, 490-490.	1.4	43
20	Elevated Axicabtagene Ciloleucel (CAR-19) Expansion By Immunophenotyping Is Associated with Toxicity in Diffuse Large B-Cell Lymphoma. Blood, 2018, 132, 576-576.	1.4	4
21	Target Antigen Downregulation and Other Mechanisms of Failure after Axicabtagene Ciloleucel (CAR19) Therapy. Blood, 2018, 132, 4656-4656.	1.4	11